Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations. Issue 2 (19th October 2020)

• Record Type: Journal Article
• Authors: Takeda, Atsushi; Takahashi, Ryosuke; Tsuboi, Yoshio; Nomoto, Masahiro; Maeda, Tetsuya; Nishimura, Akihisa; Yoshida, Kazuo; Hattori, Nobutaka
• Is Part Of: Movement disorders. Volume 36:Issue 2(2021)
• Page Start: 415
• Page End: 423
• Publication Date: 2020-10-19
• Subjects: Japanese -- opicapone -- Parkinson's disease -- randomized controlled trial; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.28322
• Languages: English
• ISSNs: 0885-3185

Abstract

ABSTRACT: Objectives: This placebo‐controlled, randomized study evaluated the efficacy and safety of opicapone 25‐mg and 50‐mg tablets in Japanese levodopa‐treated patients with Parkinson's disease and motor fluctuations. Methods: Japanese adults (n = 437, age 39–83 years) with Parkinson's disease (United Kingdom Parkinson's Disease Society criteria) received opicapone 25‐mg (n = 145), opicapone 50‐mg (n = 145), or placebo (n = 147) tablets over the double‐blind treatment period (14–15 weeks). The primary efficacy assessment was change in OFF‐time; secondary efficacy assessments included OFF/ON‐time responders (≥1 hour change from baseline), total ON‐time, ON‐time with and without troublesome dyskinesia, and Unified Parkinson's Disease Rating Scale. Results: The least squares mean (standard error) change in OFF‐time from baseline to the last visit was −0.42 (0.21) hour for the placebo group, −1.16 (0.22) hour for the opicapone 25 mg group, and −1.04 (0.21) hour for the opicapone 50 mg group. The percentage of ON‐time responders, changes in total ON‐time/ON‐time without troublesome dyskinesia, and Unified Parkinson's Disease Rating Scale II (at OFF) all showed statistically significant improvements versus placebo for both opicapone tablet doses ( P < 0.05). Unified Parkinson's Disease Rating Scale III (at ON) was improved versus placebo in patients who received opicapone 50 mg ( P < 0.05). Adverse events were more common in patients treated with opicapone 25 mg (60.0%) or opicapone 50 mg (54.5%) versus placebo (48.3%). The most commonly reported adverse event was dyskinesia (placebo, 2.7%; opicapone 25 mg, 9.0%; opicapone 50 mg, 12.4%). Conclusions: In Japanese patients, both opicapone 25 and 50 mg were significantly more effective than placebo with no dose‐dependent difference in efficacy, and both doses were well tolerated. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.